Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Circulating matrix metalloproteinase-2 and -9 enzyme activities in the children with ventricular septal defect.

Cheng KS, Liao YC, Chen MY, Kuan TC, Hong YH, Ko L, Hsieh WY, Wu CL, Chen MR, Lin CS.

Int J Biol Sci. 2013 Jun 12;9(6):557-63. doi: 10.7150/ijbs.6398. Print 2013.

2.

Mechanisms of pulmonary hypertension related to ventricular septal defect in congenital heart disease.

Pan X, Zheng Z, Hu S, Li S, Wei Y, Zhang Y, Cheng X, Ma K.

Ann Thorac Surg. 2011 Dec;92(6):2215-20. doi: 10.1016/j.athoracsur.2011.07.051. Epub 2011 Oct 28.

PMID:
22035778
3.

Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.

Dellalibera-Joviliano R, Jacob-Ferreira AL, Joviliano EE, Tanus-Santos JE, Evora PR.

Vasc Med. 2012 Apr;17(2):73-8. doi: 10.1177/1358863X11435979. Epub 2012 Mar 8.

PMID:
22402936
4.

Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.

Roldán V, Marín F, Gimeno JR, Ruiz-Espejo F, González J, Feliu E, García-Honrubia A, Saura D, de la Morena G, Valdés M, Vicente V.

Am Heart J. 2008 Jul;156(1):85-91. doi: 10.1016/j.ahj.2008.01.035.

PMID:
18585501
5.

Percutaneous closure of perimembranous ventricular septal defects with Amplatzer occluders--a single centre experience.

Szkutnik M, Kusa J, Białkowski J.

Kardiol Pol. 2008 Sep;66(9):941-7; discussion 948-9.

6.

Closure of perimembranous ventricular septal defect using transcatheter technique versus surgical repair.

Pawelec-Wojtalik M, Wojtalik M, Mrówczyński W, Surmacz R.

Kardiol Pol. 2005 Dec;63(6):595-602; discussion 603-4.

PMID:
16380857
7.
8.

Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities.

Jacob-Ferreira AL, Passos CJ, Jordão AA, Fillion M, Mergler D, Lemire M, Gerlach RF, Barbosa F Jr, Tanus-Santos JE.

Basic Clin Pharmacol Toxicol. 2009 Oct;105(4):281-8. doi: 10.1111/j.1742-7843.2009.00443.x. Epub 2009 Jul 6.

11.

Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease.

Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS, Lian JD.

Clin Chim Acta. 2006 Apr;366(1-2):243-8. Epub 2005 Nov 28.

PMID:
16313894
12.

Matrix metalloproteinases and left ventricular function and structure in spinal cord injured subjects.

Schreiber R, Paim LR, de Rossi G, Matos-Souza JR, Costa E Silva Ade A, Souza CM, Borges M, Azevedo ER, Alonso KC, Gorla JI, Cliquet A Jr, Nadruz W Jr.

Clin Chim Acta. 2014 Nov 1;437:136-40. doi: 10.1016/j.cca.2014.07.018. Epub 2014 Jul 23.

PMID:
25064800
13.

IGF-II and MMP9 as surgical repair indicators of ventricular septal defects.

Tsai CY, Lai CH, Chang MH, Jong GP, Cheng YC, Tsai FJ, Tsai CH, Kuo WH, Hsieh DJ, Huang CY.

Clin Chim Acta. 2011 Apr 11;412(9-10):761-5. doi: 10.1016/j.cca.2011.01.005. Epub 2011 Jan 14.

PMID:
21238444
14.

Surgical management of ventricular septal defect with aortic valve prolapse: clinical considerations and results.

Brauner R, Birk E, Sahar G, Blieden L, Vidne BA.

Eur J Cardiothorac Surg. 1995;9(6):315-9.

PMID:
7546804
15.

Plasma levels of metalloproteinases-9 and -2 in the acute and subacute phases of type A and type B aortic dissection.

Sangiorgi G, Trimarchi S, Mauriello A, Righini P, Bossone E, Suzuki T, Rampoldi V, Eagle KA.

J Cardiovasc Med (Hagerstown). 2006 May;7(5):307-15.

PMID:
16645407
16.

Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy.

Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno GL, Franchi M, Guidi GC.

J Clin Lab Anal. 2009;23(2):88-92. doi: 10.1002/jcla.20295.

PMID:
19288452
17.

Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure.

Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, Olivotti L, Rossettin P, Barsotti A, Ghigliotti G.

Eur J Clin Invest. 2003 Aug;33(8):648-56.

PMID:
12864774
18.

Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty.

Kuliczkowski W, Urbaniak J, Hallén J, Woźniak M, Poloński L, Mysiak A, Atar D, Zembala M, Serebruany V.

Kardiol Pol. 2013;71(5):453-63. doi: 10.5603/KP.2013.0091.

19.

Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Niebroj-Dobosz I, Janik P, Sokołowska B, Kwiecinski H.

Eur J Neurol. 2010 Feb;17(2):226-31. doi: 10.1111/j.1468-1331.2009.02775.x. Epub 2009 Oct 1.

PMID:
19796283
20.

Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.

Muniz JJ, Lacchini R, Belo VA, Nobre YT, Tucci S Jr, Martins AC, Tanus-Santos JE.

Int J Impot Res. 2012 Jan-Feb;24(1):38-43. doi: 10.1038/ijir.2011.44. Epub 2011 Sep 15.

PMID:
21918531

Supplemental Content

Support Center